Biography
Dr. Bharadwaj is fellowship-trained in blood and marrow transplantation, cellular therapy, hematology, and oncology. She is an instructor in the Stanford School of Medicine Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.
Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.
She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in Leukemia and Lymphoma and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book Precision Medicine in Oncology.
Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.
Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.
Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology.
Dr. Bharadwaj focuses her expertise on diagnosing and treating cancer in blood and bone marrow. For each patient, she develops a personalized, comprehensive, and compassionate care plan. In her diverse experience as a physician and scientist, she has served as an internal medicine doctor, hospitalist, hematologist, oncologist, and blood and marrow transplantation specialist. Dr. Bharadwaj has a degree in clinical research and is currently conducting clinical trials in transplant and cellular therapy.
She has participated in research studies of advances in therapy for chronic lymphocytic leukemia, melanoma, and breast cancer. She has co-authored articles published in Leukemia and Lymphoma and elsewhere. Topics include advances in cell transplantation. She also co-wrote the chapter on genome-driven personalized cancer therapy in the book Precision Medicine in Oncology.
Dr. Bharadwaj has made presentations at meetings of the American Society of Hematology, American Society of Clinical Oncology, and other associations.
Subjects include racial, demographic, and socioeconomic disparities in the treatment of patients with acute myeloid leukemia.
Dr. Bharadwaj is a member of the American Society for Transplantation and Cellular Therapy, American Society of Hematology, and American Society of Clinical Oncology.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Hematology (2021)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2021)
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2021) CA
-
- Fellowship: Cook County Health Hematology Oncology Fellowship (2020) IL
- Residency: John H Stroger Jr Hospital of Cook County Internal Medicine Residency (2013) IL
- Internship: University of Illinois College of Medicine at Peoria (2011) IL
- Medical Education: Kasturba Medical College Mangalore (2006) India
Honors & Awards
- ASTCT Clinical Research Training Course Scholar, ASTCT (2022)
- Organizational Excellence Award, South Zone Pharmacology Conference, Mangalore, India
-
Publications
-
Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation
Nathan, S., Bharadwaj, S., Luke, K., Kalas, L., Katz, D. A., Hussain, M. J., … Ustun, C. (2020). Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. LEUKEMIA & LYMPHOMA, 61(8), 2008–2011. -
Gender and glaucoma: what we know and what we need to know
Vajaranant, T. S., Nayak, S., Wilensky, J. T., & Joslin, C. E. (2010). Gender and glaucoma: what we know and what we need to know. CURRENT OPINION IN OPHTHALMOLOGY, 21(2), 91–99. -
Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes.
Abraham, I. E., Rauscher, G. H., Patel, A. A., Pearse, W., Rajakumar, P., Burkart, M., … Khan, I. (1800). Structural Racism is a Mediator of Disparities in Acute Myeloid Leukemia Outcomes. Blood. -
-
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., … Natkunam, Y. (2022). Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance. MODERN PATHOLOGY. SPRINGERNATURE. -
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Younes, S., Libert, D., Zhao, S., Johnsrud, A., Bharadwaj, S., Majzner, R., … Natkunam, Y. (2022). Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance. LABORATORY INVESTIGATION. SPRINGERNATURE. -
Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy
Nie, E., Ahmadian, S., Bharadwaj, S., Acosta-Alvarez, L., Threlkeld, Z., Frank, M., … Vogel, H. (2022). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. OXFORD UNIV PRESS INC. -
Geriatrics assessment in older adults referred for hematopoietic cell transplantation.
Sossenheimer, P. H., Bharadwaj, S., Johnston, L., & Periyakoil, V. S. (2022). Geriatrics assessment in older adults referred for hematopoietic cell transplantation. Journal of the American Geriatrics Society. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie, E. H., Ahmadian, S. S., Bharadwaj, S. N., Acosta-Alvarez, L., Threlkeld, Z. D., Frank, M. J., … Vogel, H. (2023). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. Journal of Neuropathology and Experimental Neurology. -
Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY. -
Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY. -
The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY. -
Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY. -
Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., … Hansen, D. K. (2022). Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience. BLOOD. AMER SOC HEMATOLOGY. -
Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance.
Younes, S., Zhao, S., Bharadwaj, S., Mosquera, A. P., Libert, D., Johnsrud, A., … Natkunam, Y. (2023). Detection of Aberrant CD58 Expression in a Wide Spectrum of Lymphoma Subtypes: Implications for Treatment Resistance. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 100256. -
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., … Hansen, D. K. (2023). Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. -
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., … Janakiram, M. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 13(1), 158. -
Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances. -
TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert, D., Zhao, S., Younes, S., Mosquera, A. P., Bharadwaj, S., Ferreira, C., & Natkunam, Y. (2023). TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy. The American Journal of Surgical Pathology. -
Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances. -
Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient.
Lee, D., Goyal, A., Wang, W. L., Ananth, S., Lau, E., Binkley, M. S., … Dahiya, S. (2024). Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B-cell lymphoma in an adolescent patient. EJHaem, 5(1), 153–156. -
CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY. -
Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL)
Bharadwaj, S., Lau, E., Hashmi, A., Hamilton, M. P., Jensen, A., Goyal, A., … Dahiya, S. (2023). Analysis of PET-CT Derived Radiomic Biomarkers with Efficacy, Safety, and Expansion of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection
Ananth, S., Su, Y.-J., Hamilton, M. P., Agarwal, N., Weng, W.-K., Dahiya, S., … Frank, M. J. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. BLOOD. AMER SOC HEMATOLOGY. -
Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY. -
Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Bharadwaj, S., Lau, E., Goyal, A., Hamilton, M. P., Srinagesh, H., Jensen, A., … Dahiya, S. (2023). Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL)
Goyal, A., Bharadwaj, S., Lee, D., Lau, E., Hamilton, M. P., Jensen, A., … Dahiya, S. (2023). Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor-T (CAR T) Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y.-J., Kramer, A. M., Reschke, A., … Frank, M. J. (2023). CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature. BLOOD. AMER SOC HEMATOLOGY. -
Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)
Dahiya, S., Spiegel, J. Y., Lee, D., Mohammed, T., Lutfi, F., Goyal, A., … Jain, M. D. (2023). Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL). BLOOD. AMER SOC HEMATOLOGY. -
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., … Muffly, L. (2024). CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia. -
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances. -
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7). -
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood.
-
Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CA
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereHematology Program Palo Alto, CA
Palo Alto, CA
Hematology Program
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(42 reviews)
I feel very comfortable and safe with the care of Dr Sushma Bharadwaj
Doctor B is a great doctor!!
Doctor Sushma Bharadwaj., is amazing
Dr. Sushma Bharadwaj is very professional and polite. And is very thorough.
Great doctor thank you!
I’m impressed by the attention I received from Dr. Bharadwaj, including the initiative she’s taking to explore possible treatments, the thoroughness of her explanations, her patience answering questions and her empathy.
She’s always pepaired and knows my case well. Importantly, she takes the time to listen and give you the time needed to completely answer. Any questions or concerns. Very caring, Compassionate And skilled doctor. Highly recommended.
Love her
Professional, compassionate, bright and cheerful!
I really like her, very kind and professional and very good at explaining things.
Doctor Sushma, is amazing and professional.
Dr. Sushma Bharadwaj is a caring doctor. She listens to my comments and concerns and addresses all concerns. I feel very comfortable speaking with her. She is Kind, Polite, Professional and Compassionate. Thank you Dr. Sushma Bharadwaj.
Dr. Bharadwaj is really concerned about my wellness and recovery â ¤ï¸ â€ ðŸ©¹ Her concern is highly appreciated!
Dr Bharadwaj is a very kind and compassionate person and is very patient explaining medical procedures. I feel very grateful that she is my doctor,
Hugh Mallaney
She a great Dr she explains things so I understand stand and I never feel rushed.
She is amazing and very knowledgeable
She very easy to talk to and very through I enjoy talking to her
She’s a very nice person
She always takes the time necessary for a complete consultation. This is very much appreciate it.
Very nice and informative and to the point and listen to my input and suggestion and very clear on her diagnosis and her thoughts.
She was on time with her video visits and had all the information from my tests available for me . She was knowledgeable and extremely helpful about my choices for treatment. She is a credit to her profession and a caring Doctor .
Wonderful Doctor and easy to understand and work with.😀
I am thrilled that we will be able to consider a move forward with the transplant. It made my month.
Thanks
Dr B is fantastic, very thorough and dedicated
She is a great doctor I’m so lucky to have her as my doctor
She's been great! Thorough, patient, supportive and informative. She made an extremely tense and scary process one I thought I could do, after her patience and encouragement. She's a keeper!
All the medical staff are very professional and helpful. Facilities are clean and modern.
Makes you feel comfortable asking questions, doesn’t rush you
She’s a great doctor I’m very lucky to have her taking care or me.
Dr. Bharadwaj is very compassionate, caring and treats patients so well! Anu is aso very professional and caring. The best team ever!!!
Truly an awesome Doctor I’m very happy I was assigned to her
Thank you and Anu for your help
I am appreciative and grateful to Dr Bharadwaj and her team for managing me through this treatment process skillfully and successfully.
Loved Dr bhardwaj, anu, and the Social Worker. My dad has had such a rough ride since he got his lymphoma. Everyone in stanford gave such a positive vibe. Invluding the two lab assistantsthat took my dads blood. I'm so happy with how the dr. Explained everything to him and asked me to tell him too. When we left i could see my dad feeling happier since he knew more of whatwas going on with him and how to proceed.
Very informative. Thk u
I think Dr Bharadwaj is a very good and thorough Doctors
Dr Bharadwaj has been a very good listener and has consistently explained everything regarding my care in layman’s language so that there hasn’t been any misunderstandings. She has always been professional and compassionate and caring.
Dr Sushma Bharadwaj is very easy to talk to. She explains completely of whatever issue the patient has. She is caring, thoughtful, engaged. I am grateful and thankful that she's my bone marrow transplant doctor, made the process less rough. I'd also like to thank her nurse coordinator, Anu Stephen. Anu also has the same above qualities.
Hey Dr. B,
Just wanted to thank you for today’s call. I’m extremely happy to hear that my test results were good! It’s nice to know someone is looking out for me.
Look forward to our face to face in January.
Happy Holidays!!
Staff is always very professional and thorough. I appreciate each one of them.
Very kind and knowledgeable
Comments for the doctor:
Thank you doctor for going over everything with me. I appreciate all that you and your team are doing for me and everyone else in need. I’m truly thankful.
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records